Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-10-09
2007-10-09
Rawlings, Stephen L. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S350000, C530S387700, C436S064000
Reexamination Certificate
active
10257021
ABSTRACT:
The present invention features methods of diagnosing and prognosticating ovarian tumors by detecting increased expression of an ovarian tumor marker gene in a subject or in a sample from a subject. Also featured are kits for the aforementioned diagnostic and prognostic methods. In addition, the invention features methods of treating and preventing ovarian tumors, and methods of inhibiting the growth or metastasis of ovarian tumors, by modulating the production or activity of an ovarian tumor marker polypeptide. Further featured are methods of inhibiting the growth or metastasis of an ovarian tumor by contacting an ovarian tumor cell with an antibody that specifically binds an ovarian tumor marker polypeptide.
REFERENCES:
patent: 5356817 (1994-10-01), Cole
patent: WO99/53040 (1999-10-01), None
Morin. Cancer Res. Nov. 1, 2005; 65 (21):9603-9606.
Tsukita et al. J. Cell Biol. Apr. 3, 2000; 149 (1): 13-16.
Swisshelm et al. (Adv. Drug Delivery Rev. 2005; 57; 919-928).
Rae et al. (International Journal of Cancer. 2000; 88: 726-732).
Alon et al., “Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays.”Proc Natl Acad SciUSA 96:6745-6750 (Jun. 1999).
Auersperg et al., “E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium.”Proc Natl Acad SciUSA 96:6249-6254 (May 1999).
Bast et al., “Reactivity of a monoclonal antibody with human ovarian carcinoma.”J Clin Invest68(5):1331-1337 (Nov. 1981).
Berezowski et al., “Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma.”Mod Pathol9(4):426-429 (1996).
Datson et al., “MicroSAGE: a modified procedure for serial analysis of gene expression in limited amounts of tissue.”Nucl Acids Res27(5):1300-1307 (1999).
DePasquale et al., “Differential expression of the pRb2 tumor suppressor gene in human epithelial ovarian carcinoma compared to ovarian tumors of low malignant potential and normal ovaries.”Proc Am Assoc Cancer Res Ann38:109 (1997) (Abstract).
Eisen et al., “Cluster analysis and display of genome-wide expression patterns.”Proc Natl Acad SciUSA 95:14863-14868 (Dec. 1998).
Goodman et al., “Recombinant Adeno-Associated Virus-Mediated Gene Transfer Into Hematopoietic Progenitor Cells.”Blood84(5):1492-1500 (Sep. 1, 1994).
Hough et al., “Comparison of Sage-Generated Expression Profiles Between Ovarian Cancer and Human Ovarian Surface Epithelium.”Proc Am Assoc Cancer Res Ann41:310-311 (Mar. 2000) (Abstract).
Hough et al., “Large-Scale Serial Analysis of Gene Expression Reveals Genes Differentially Expressed in Ovarian Cancer.”Cancer Res60(22):6281-6287 (Nov. 15, 2000).
Hough et al., “Use of SAGE to study gene expression in ovarian cancer.”Proc Am Assoc Cancer Res Ann40:34 (Mar. 1999) (Abstract).
Lagendijk et al., “Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites.”Hum Pathol29(5):491-497 (May 1, 1998).
Lal et al., “A Public Database for Gene Expression in Human Cancers.”Cancer Res59:5403-5407 (Nov. 1, 1999).
Luo et al., “Establishment of long-term in vitro cultures of human ovarian cystadenomas and LMP tumors and examination of their spectrum of expression of matrix-degrading proteinases.”Gynecol Oncol67(3):277-284 (Dec. 1997).
Maines-Bandiera et al., “Increased E-cadherin expression in ovarian surface epithelium: an early step in metaplasia and dysplasia.”Int J Gynecol Pathol16(3):250-255 (Jul. 1, 1997).
Mok et al., “Molecular Cloning of Differentially Expressed Genes in Human Epithelial Ovarian Cancer.”Gynecol Oncol52(2):247-252 (Feb. 1994).
Ross et al., “Systematic variation in gene expression patterns in human cancer cell lines.”Nat Genet24(3):227-235 (Mar. 1, 2000).
Schink, “Current initial therapy of stage III and IV ovarian cancer: challenges for managed care.”Semin Oncol26(1Suppl 1):2-7 (Feb. 1, 1999).
Scully, “Pathology of ovarian cancer precursors.”J Cell BiochemSuppl 23:208-218 (Jan. 1, 1995).
Velculescu et al., “Serial Analysis of Gene Expression.”Science270(5235):484-487 (Oct. 20, 1995).
Zhang et al., “Gene expression profiles in normal and cancer cells,”Science276(5316):1268-1272 (May 23, 1997).
Hough Colleen D.
Morin Patrice J.
Pizer Ellen S.
Sherman-Baust Cheryl A.
Needle & Rosenberg P.C.
Rawlings Stephen L.
The United States of America as represented by the Secretary, De
LandOfFree
Tumor markers in ovarian cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor markers in ovarian cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor markers in ovarian cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3831857